Microcarrier Cell Culture Patents: Leaders & White Space 2026
- Concentrated at the top. The five leading assignees together hold 42.0% of all 336 records in scope, and the leader alone accounts for 46 records.
- Filing has cooled from its 2022 peak. Activity climbed to 36 records in 2022, then fell from 19 in 2021 to 6 in 2024, a -68% move over that span — though 2025-26 counts are still filling in.
- Bioreactor apparatus claims dominate. C12M bioreactor and enzyme-apparatus classifications sit on 58.0% of records, second only to C12N genetic-engineering classifications at 83.9%.
Filing growth compares 2021 (19 records) with 2024 (6) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 336 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks patent filings at the intersection of microcarrier-based adherent cell culture and perfusion control — the mechanics of keeping cells fed and waste cleared in continuous or semi-continuous bioreactor operation. The search combines culture-format language (microcarrier culture, adherent cell culture) with process-control language (perfusion rate, bleed control, residence time, nutrient renewal, waste removal, steady state), scoped to the core bioprocessing IPC classes C12N, C12M and C12M1/12.
Coverage runs from 2015 through the 2026-07-31 data cut-off, spanning 336 published records and 336 families across 95 ranked assignees. Because publication trails filing by roughly 18 months, the most recent one to two years of the trend understate real filing activity and should be read as provisional rather than as a decline.
Filing trend and technology mix
Two views of the same 336-record dataset: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
Filings peaked in 2022, then pulled back
Annual filings rose from 6 records in 2017 to a peak of 36 in 2022, then declined to 6 by 2024 — a -68% move from the 19 filed in 2021. Treat 2025 and 2026 figures as incomplete rather than as confirmation the field is shrinking.
Apparatus claims sit alongside genetic-engineering claims
C12N (microorganisms and genetic engineering) appears on 83.9% of the 336 records and C12M (bioreactors and enzyme apparatus) on 58.0%, confirming that most filings pair a biological composition claim with a hardware or process claim. Downstream categories — A61K medicinal preparations at 14.0%, C07K peptides at 9.8%, and G06T image processing at 5.7% — show smaller but non-trivial claim activity around analytics and formulation.
Shares are the percentage of the 336 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Microcarrier Cell Culture Perfusion Culture with Eureka
This page is one run against one query. Ask Eureka your own question about microcarrier cell culture perfusion culture and every answer comes back with the patent numbers behind it.
Try EurekaA recent claim worth reading in full
Fixed-bed bioreactor with constant-flow pump/tubing system
The filing modifies a commercially-available adherent cell culture bioreactor to slow cell culture medium flow, which the applicant reports unexpectedly and substantially increases productivity of the cultured adherent cells. It also introduces a new sampling manifold and sampling method intended to reduce contamination risk during operation.US20240425792A1, published 2024-12-26
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20050106717A1 | Cell culture methods and devices utilizing gas permeable materials | 381 |
| 2 | US5266476A | Fibrous matrix for in vitro cell cultivation | 258 |
| 3 | WO2005113758A1 | Process for the production of an influenza vaccine | 174 |
| 4 | US5155034A | Three-dimensional cell to tissue assembly process | 126 |
| 5 | WO2005035728A2 | Cell culture methods and devices utilizing gas permeable materials | 110 |
| 6 | US9255243B2 | Cell culture methods and devices utilizing gas permeable materials | 94 |
| 7 | US20050054101A1 | Automated cell culture system and process | 93 |
| 8 | GB2178447A | A matrix for cell cultivation in vitro | 90 |
| 9 | US20040067585A1 | Cell cultivation surface and method of making the same | 88 |
| 10 | US8158427B2 | Cell culture methods and devices utilizing gas permeable materials | 82 |
Citation counts favour older records simply because they have had longer to accumulate citations inside this corpus — read them as a signal of influence, not of current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data actually supports
Three read-throughs from the filing pattern, technology mix and citation record — each tied to a specific figure rather than a general impression of activity.
The field has a defined leadership tier
The leading assignee holds 46 records and the fifth-ranked holds 20, with the top five together accounting for 42.0% of all 336 records in scope. That leaves a long tail across the remaining 90 ranked assignees, most with a handful of filings each.
Volume has pulled back from its 2022 high
Filings rose steadily through the late 2010s to a peak of 36 records in 2022, then fell to 6 by 2024. Several of the top-ranked assignees show zero filings in the most recent tracked year, consistent with a maturing rather than an expanding claim landscape.
Apparatus claims are as common as biological ones
C12M bioreactor and enzyme-apparatus classifications appear on more than half of all records, just behind C12N at 83.9%. Filers are protecting the hardware and process-control mechanics of perfusion alongside the underlying cell-culture composition.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to microcarrier cell culture perfusion culture, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Ecole Superieure de Physique et de Chimie Industrielles de Lyon (ESPCI Lyon) | Institut National des Sciences Appliquees de Lyon (INSA Lyon) | 11 |
| Ecole Superieure de Physique et de Chimie Industrielles de Lyon (ESPCI Lyon) | Sartorius Stedim FMT SAS | 11 |
| Ecole Superieure de Physique et de Chimie Industrielles de Lyon (ESPCI Lyon) | Centre National de la Recherche Scientifique (CNRS) | 11 |
| Ecole Superieure de Physique et de Chimie Industrielles de Lyon (ESPCI Lyon) | Universite Claude Bernard Lyon 1 | 11 |
| Institut National des Sciences Appliquees de Lyon (INSA Lyon) | Sartorius Stedim FMT SAS | 11 |
| Institut National des Sciences Appliquees de Lyon (INSA Lyon) | Centre National de la Recherche Scientifique (CNRS) | 11 |
| Institut National des Sciences Appliquees de Lyon (INSA Lyon) | Universite Claude Bernard Lyon 1 | 11 |
| Wilson Wolf Manufacturing Corp | WILSON JOHN R | 2 |
Ten co-assignee pairs appear in the dataset; the strongest cluster links an engineering school, a national research institute and a bioprocessing equipment maker at 11 shared filings each, suggesting an academic-industrial collaboration around fixed-bed and perfusion hardware.
Assignee landscape
Ninety-five assignees appear in the ranked dataset. Filing is concentrated among a small group of bioprocessing equipment and biologics manufacturers, with a long tail of single- and few-filing entrants.
A single assignee holds the top position outright
The leading assignee's 46 records outpace the fifth-ranked assignee's 20, a gap wide enough to suggest a deliberate, sustained filing programme rather than opportunistic filing.
Filing drops off quickly after the top ten
The top ten assignees combine for 61.9% of all 336 records, meaning the remaining 85 ranked assignees share under two-fifths of the field between them — mostly in single digits each.
Academic-industrial co-filing is concentrated in one cluster
The strongest co-assignee links connect a French engineering school, a national research body and a bioprocessing equipment supplier, each pairing appearing on 11 shared filings — a tight cluster likely built around fixed-bed and perfusion hardware development.
| Assignee | Recent year | YoY |
|---|---|---|
| Wilson Wolf Manufacturing Corp | 0 | — |
| Genzyme Corp | 0 | — |
| CELLINO BIOTECH INC | 0 | -100% |
| Trizell Ltd | 0 | — |
| Ares Trading SA | 0 | — |
| Schering Corp | 0 | — |
| Global Cell Solutions LLC | 0 | — |
| ID Biomedical Corporation of Quebec (Laval) | 0 | — |
Where to take this analysis
The dataset points to specific follow-up questions for freedom-to-operate and whitespace work rather than a single conclusion.
Check freedom-to-operate around fixed-bed perfusion hardware
With C12M apparatus claims on 58.0% of records and a recent, actively-cited filing from Trizell on flow-rate control, any new fixed-bed or constant-flow design should be checked against this cluster specifically.
Explore claims in EurekaWatch for renewed filing after the 2022 peak
The pullback to 6 records in 2024 could reverse once 2025-26 publications catch up; tracking the leading assignees' filing cadence is more informative than the raw year-over-year count right now.
Set up monitoring in EurekaProbe the under-claimed sensing and analytics branches
G06T image-processing classifications sit at just 5.7% of records despite growing interest in automated confluence and viability monitoring — a plausible entry point for a first-mover claim.
Run a whitespace search in EurekaCommon questions on this landscape
The dataset ranks 95 assignees, and a single company leads with 46 records against 336 total in scope. The next four ranked assignees combine with the leader for 42.0% of all records, indicating a concentrated top tier. Beyond the top ten — who together hold 61.9% of records — filing activity drops sharply into a long tail of companies with only a handful of filings each.
Filing rose from 6 records in 2017 to a peak of 36 in 2022, then fell to 6 by 2024, a -68% change from the 19 filed in 2021. However, publication typically lags filing by around 18 months, so the 2025 and 2026 figures in this dataset are still incomplete and should not be read as confirmation of a real slowdown. A clearer read on the current trajectory will only be available once those years finish publishing.
C12N, covering microorganisms and genetic engineering, appears on 83.9% of the 336 records, and C12M, covering bioreactors and enzyme apparatus, appears on 58.0% — meaning most filings combine a biological composition claim with hardware or process-control claims. Smaller but notable shares sit in A61K medicinal preparations (14.0%), C07K peptides and proteins (9.8%), and G01N material testing (9.2%). These figures overlap because a single record can carry more than one IPC classification.
The most-cited record in this corpus, US20050106717A1 on gas-permeable cell culture devices and methods, has accumulated 381 citations, with several other older gas-permeable and matrix-based culture patents also carrying high citation counts. High citation counts inside an older record reflect accumulated influence over time rather than current commercial relevance, so a new filer should treat them as markers of foundational claim territory to design around rather than as evidence those approaches are still the most active area of filing.
Apparatus-heavy branches like fixed-bed bioreactor hardware are already densely claimed, given C12M's 58.0% share of records. Lighter-claimed branches include image-based monitoring (G06T at 5.7% of records) and lab-scale apparatus integration (B01L at 6.5%), both of which sit inside the search scope but carry far less claim density than the core bioreactor and genetic-engineering classes. These are reasonable starting points for a novelty search before drafting a first claim in this field.
Research Microcarrier Cell Culture Perfusion Culture in depth with Eureka
Go past this page: query the whole microcarrier cell culture perfusion culture corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.